Zuzanna Pelc, Katarzyna Sędłak, Magdalena Leśniewska, Katarzyna Mielniczek, Katarzyna Chawrylak, Magdalena Skórzewska, Tomasz Ciszewski, Joanna Czechowska, Agata Kiszczyńska, Bas P L Wijnhoven, Johanna W Van Sandick, Ines Gockel, Suzanne S Gisbertz, Guillaume Piessen, Clarisse Eveno, Maria Bencivenga, Giovanni De Manzoni, Gian Luca Baiocchi, Paolo Morgagni, Riccardo Rosati, Uberto Fumagalli Romario, Andrew Davies, Yutaka Endo, Timothy M Pawlik, Franco Roviello, Christiane Bruns, Wojciech P Polkowski, Karol Rawicz-Pruszyński
The incidence of gastric cancer (GC) is expected to increase to 1.77 million cases by 2040. To improve treatment outcomes, GC patients are increasingly treated with neoadjuvant chemotherapy (NAC) prior to curative-intent resection. Although NAC enhances locoregional control and comprehensive patient care, survival rates remain poor, and further investigations should establish outcomes assessment of current clinical pathways. Individually assessed parameters have served as benchmarks for treatment quality in the past decades...
April 28, 2024: Cancers